Which peptides have the best community sentiment, and does the evidence match?

The short answer

Tesamorelin, CJC-1295/Ipamorelin and MOTS-c share the highest community sentiment in our data at +0.37 each. Their evidence bases are not remotely comparable. Tesamorelin is FDA-approved with two phase 3 trials; MOTS-c has almost no published human administration data at all. Sentiment cannot tell these apart.

Evidence tier: Tier 1 for tesamorelin (FDA-approved, two phase 3 RCTs); Tier 2–3 for CJC-1295 and ipamorelin individually, Tier 4 for the combination; Tier 4 for MOTS-c administration in humans. Sentiment data is Tier 3 — our own analysis of 1,992 public posts. Educational content, not medical advice.

The key points:

• Identical sentiment, incomparable evidence — +0.37 spans FDA-approved to never-properly-trialled.
• Tesamorelin cut visceral fat ~15.4% vs placebo across 806 pooled phase 3 participants.
• No published human RCT exists of the CJC-1295/Ipamorelin combination, only of its components.
• MOTS-c's famous "12-fold" finding measured the body's own peptide after exercise — nobody was injected.
• All three are flat or shrinking in share of conversation. The best-liked compounds are the quietest.

Why look at sentiment rather than volume?

Evidence tier: 3 — our data.

In our analysis of 1,992 classified public posts from June to August 2026, the fastest-growing compounds were the ones an FDA advisory committee had just voted on. Volume tracked a news cycle, as we covered in which peptides are gaining traction.

Sentiment behaves differently. It reflects what people who actually took something say about it afterwards, and it moves more slowly. Three compounds tie at the top of our sentiment table at +0.37:

• MOTS-c — Sentiment: +0.37 · Mentions (30d): 91 · Change: +8%
• Tesamorelin — Sentiment: +0.37 · Mentions (30d): 47 · Change: −19%
• CJC-1295 / Ipamorelin — Sentiment: +0.37 · Mentions (30d): 40 · Change: −25%

Two of the three are declining in share of conversation. These are quietly well-regarded compounds, not hyped ones — which is itself worth noting, because it is the opposite of what a trending list surfaces.

But the interesting part is what happens when you check the evidence behind each.

What does tesamorelin actually have behind it?

Evidence tier: 1 — FDA-approved, two phase 3 RCTs.

By some distance the strongest of the three, and one of the strongest of any peptide discussed in this space.

Tesamorelin is an approved drug. The FDA approved it as Egrifta in November 2010 for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy — still the only medication approved in the US for that indication. A newer formulation, Egrifta WR (tesamorelin F8), was approved more recently and moves reconstitution from daily to weekly.

The approval rests on two phase 3 multi-centre, randomised, double-blind, placebo-controlled trials. In a pooled analysis of 806 participants, tesamorelin reduced visceral adipose tissue by approximately 15.4% versus placebo at 26 weeks (p<0.001), with significant reductions in waist circumference.

Mechanistically it is a synthetic analogue of growth hormone releasing factor, acting on pituitary cells to stimulate endogenous GH synthesis and release — a physiological route rather than exogenous GH.

Two caveats matter and are frequently dropped. The trials were conducted in people with HIV-associated lipodystrophy, a specific metabolic condition; generalisation to healthy adults seeking body-composition changes is an extrapolation, not a finding. And cardiovascular benefit was not studied — the short-term trials did not address cardiovascular risk, and long-term cardiovascular outcomes remain unstudied.

Is the CJC-1295/Ipamorelin combination actually tested?

Evidence tier: 2 for components, 4 for the combination.

The components are, the combination isn't.

CJC-1295 is a long-acting GHRH analogue. A phase 2 trial in healthy adults aged 21–61 found dose-dependent increases in growth hormone and IGF-1, with mean IGF-1 up 35–85% depending on dose, sustained for six or more days after a single injection. That is real human pharmacokinetic data and it is why the compound is taken seriously.

Ipamorelin is a selective ghrelin mimetic producing pulsatile GH release without the cortisol and prolactin effects of earlier secretagogues.

But there are no published human randomised controlled trials of the two used together. The stack that people actually take — and that this +0.37 sentiment refers to — has not itself been trialled. What exists is component evidence plus a plausible rationale for combining a GHRH analogue with a ghrelin mimetic.

There is also a regulatory wrinkle worth knowing. CJC-1295 is classified as an FDA 503A Category 2 bulk drug substance, which prohibits its use in compounding by licensed 503A pharmacies in the US. It has no FDA-approved indication. That places it in a very different position from tesamorelin, and — notably — on the opposite side of the line from MOTS-c, which an advisory committee recommended for 503A listing in July 2026.

Two compounds with identical community sentiment, one recommended for compounding and one prohibited from it.

What human evidence does MOTS-c have?

Evidence tier: 4 — essentially none for administration.

This is where the gap between sentiment and evidence is widest, and the detail is worth getting right because it is almost universally misreported.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, in the 12S rRNA region — genuinely novel biology, and part of a class (mitochondrial-derived peptides) that suggests mitochondria act as signalling organs rather than just power plants. The animal data on insulin sensitivity, obesity and physical performance is interesting.

The finding everyone cites is that a single bout of exercise raised MOTS-c roughly 12-fold in human skeletal muscle and about 1.6-fold in blood. It gets repeated as evidence that MOTS-c is an "exercise mimetic."

That study measured the body's own MOTS-c. Nobody was injected with anything. It shows exercise raises endogenous MOTS-c — which is a reason to hypothesise that administering it might do something, not evidence that it does. Those are different claims, and the second does not follow from the first.

Human research to date has largely measured naturally occurring MOTS-c rather than testing it as a drug, and the associations are context-dependent — circulating levels do not map cleanly onto better metabolic health across studies. MOTS-c is not FDA-approved, and anti-doping and medical bodies describe it as experimental.

The first properly designed test is only now running: NCT07505745, a phase 2a randomised, double-blind, placebo-controlled study in adults with prediabetes and overweight or obesity. That trial will produce the first real answer.

What does this tell you about community sentiment?

Evidence tier: 3 — our data, interpreted.

That it is measuring something real, and that the something is not evidence quality.

Sentiment of +0.37 sits identically on a drug with two phase 3 trials and FDA approval, a combination that has never been trialled as a combination, and a peptide with essentially no published human administration data. If community feeling tracked evidence, that spread would be impossible.

What sentiment plausibly does track is experience quality: tolerability, absence of unpleasant side effects, whether the subjective effect matches expectation, and whether people feel misled. On those measures all three may genuinely deserve to score well. Notably, all three are also GH-axis or metabolic compounds with gradual, cumulative effects — a profile less likely to generate the dramatic disappointment that drags sentiment down for compounds sold on rapid transformation.

The practical implication is straightforward. Community sentiment is a useful signal about what using something is like. It is not a signal about whether it works, and it cannot rank compounds by evidence — as this month's data demonstrates about as cleanly as any dataset could.

Limitations

This is educational content, not medical advice.

• Sentiment is machine-classified and missing on a substantial share of Reddit posts, so these averages rest on a subset.
• Two months of data with one large regulatory news event inside the window.
• Tesamorelin's trials were in HIV-associated lipodystrophy. Applying those results to healthy adults is extrapolation.
• Tesamorelin's cardiovascular effects are unstudied, short- and long-term.
• CJC-1295 is FDA 503A Category 2 — prohibited for compounding in the US, no approved indication.
• MOTS-c administration in humans is largely untested. NCT07505745 is ongoing; treat everything before it as hypothesis.
• Self-selected posters. People who had a bad experience often stop posting rather than report it.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Three compounds sit tied at the top of our sentiment table, and the evidence behind them spans nearly the entire range that exists. Tesamorelin is an approved drug with two phase 3 trials and an effect size — 15.4% visceral fat reduction versus placebo — that most peptides can only aspire to. CJC-1295/Ipamorelin has genuine component data and no trial of the actual combination people take, plus a regulatory status that prohibits US compounding. MOTS-c has fascinating biology, striking animal data, and almost nothing in humans that involves administering it to anyone.

Community sentiment rated all three identically.

That is not a criticism of the community. People are reporting what using something felt like, accurately and in good faith, and that information has real value — it is exactly what the published literature never captures. It simply answers a different question from the one most readers think they are asking. If you want to know whether a compound is pleasant and tolerable to use, sentiment is your best available guide. If you want to know whether it works, you have to go and read the trials, and this month three compounds that feel identical from the outside look nothing alike once you do.

Related on this site

• Which peptides are gaining traction in 2026
• Tesamorelin
• MOTS-c
• Why most longevity peptide stacks don't survive evidence scrutiny
• Live community signal feed
• Our evidence-tier framework

References

• FDA approval of tesamorelin (Egrifta), November 2010 — reduction of excess abdominal fat in HIV-associated lipodystrophy; two phase 3 randomised, double-blind, placebo-controlled trials, 806 pooled participants, ~15.4% visceral adipose tissue reduction vs placebo at 26 weeks (p<0.001).
• FDA approval of EGRIFTA WR (tesamorelin F8) — weekly reconstitution formulation.
• CJC-1295 phase 2 data in healthy adults aged 21–61 — dose-dependent GH and IGF-1 increase, mean IGF-1 +35–85%, sustained ≥6 days after a single injection. No published RCT of the CJC-1295/Ipamorelin combination.
• CJC-1295 FDA 503A Category 2 bulk drug substance classification — prohibited for 503A compounding in the US.
• MOTS-c exercise study — ~12-fold rise in human skeletal muscle and ~1.6-fold in blood following a single bout of exercise, measuring endogenous peptide; no administration.
• NCT07505745 — phase 2a randomised, double-blind, placebo-controlled trial of MOTS-c in adults with prediabetes and overweight/obesity.
• My Peptide Story community signal pipeline — 1,992 classified public posts, 6 June to 7 August 2026.